Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX:
TLRY), a leading global cannabis-lifestyle and consumer packaged
goods company inspiring and empowering the worldwide community to
live their very best life, today announced the expansion of its
medical cannabis product offering in Australia and a new medical
cannabis e-learning platform for healthcare providers.
Denise Faltischek, Head of International and
Chief Strategy Officer, said, “Tilray is transforming the industry
globally with our highly scalable footprint and portfolio of
diverse cannabis products. As medical cannabis demand increases
worldwide, we remain committed to providing healthcare
professionals and patients with safe and reliable access to the
highest-quality medical cannabis products.” Ms. Faltischek
continued, “After listening to patient feedback and leveraging
learnings from our operations in Germany, we are excited to be
introducing new products in Australia that meet consumer
needs.”
Tilray's product offering
in Australia approved under the Therapeutic Goods
Administration (TGA) Special Access and Authorized Prescriber
Scheme is centered around its whole flower options ranging from
balanced 1:1 whole flower (THC 10 CBD 10), including mid-range
(17), and high THC (25) varieties of 15g bag GMP-Certified medical
cannabis whole flower.
George Polimenakos, General Manager, Tilray
Australia, and New Zealand, said, "We are committed to providing
reliable access to patients in need with pharmaceutical-grade
medical cannabis products and are pleased to be expanding our
medical cannabis offerings in Australia." Mr. Polimenakos
continued, “On a related note, cannabis education is paramount to
everything we do and are therefore excited to offer healthcare
professionals with the tools they need to learn about cannabis
through our new e-learning platform.”
Tilray’s new medical cannabis educational
platform for healthcare professionals is built on the importance of
understanding the benefits derived from medical cannabis use. To
date, Tilray has successfully introduced multiple medical cannabis
workshops across Australia and New Zealand, educating hundreds of
health care practitioners in 2021.
In addition to supplying hospitals and
pharmacies, Tilray is a proud partner with several
leading research institutions, including the Murdoch
Children's Research Institute in Australia, studying the
effectiveness of Tilray medical cannabis as a treatment
for pediatric patients with Intellectual Disabilities suffering
from Severe Behavioral Problems; a clinical trial in partnership
with The Government of New South
Wales and University of Sydney Chris O'Brien
Lifehouse to develop a novel treatment for
chemotherapy-induced nausea, and a study led by the University
of Sydney examining the effects of driving under the influence
of cannabis.
Today, Tilray is one of the leading providers of
GMP-certified medical cannabis to patients, physicians, pharmacies,
hospitals, governments, and researchers across the globe.
For more information about Tilray medical
cannabis in Australia and New Zealand, visit:
https://www.tilray.com.au/
For more information about the Tilray medicinal
cannabis workshops in Australia, visit:
https://tilray.medihuanna.com/
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY),
is a leading global cannabis-lifestyle and consumer packaged goods
company with operations in Canada, the United States, Europe,
Australia, and Latin America that is changing people’s lives for
the better – one person at a time – by inspiring and empowering the
worldwide community to live their very best life by providing them
with products that meet the needs of their mind, body, and soul and
invoke a sense of wellbeing. Tilray’s mission is to be the trusted
partner for its patients and consumers by providing them with a
cultivated experience and health and wellbeing through
high-quality, differentiated brands and innovative products. A
pioneer in cannabis research, cultivation, and distribution,
Tilray’s unprecedented production platform supports over 20 brands
in over 20 countries, including comprehensive cannabis offerings,
hemp-based foods, and alcoholic beverages.
For more information on how we open a world of
wellbeing, visit www.Tilray.com.
Forward-Looking Statements
Certain statements in this communication that
are not historical facts constitute forward-looking information or
forward-looking statements (together, “forward-looking statements”)
under Canadian securities laws and within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, that are intended
to be subject to the “safe harbor” created by those sections and
other applicable laws. Forward-looking statements can be identified
by words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: ; the Company’s
ability to commercialize new and innovative products worldwide,
including in Australia; expectations regarding worldwide medical
cannabis demand; and expectations regarding regulatory approval and
commercialization of medical cannabis products. Many factors could
cause actual results, performance or achievement to be materially
different from any forward-looking statements, and other risks and
uncertainties not presently known to the Company or that the
Company deems immaterial could also cause actual results or events
to differ materially from those expressed in the forward-looking
statements contained herein. For a more detailed discussion of
these risks and other factors, see the most recently filed annual
information form of Tilray and the Annual Report on Form 10-K (and
other periodic reports filed with the SEC) of Tilray made with the
SEC and available on EDGAR. The forward-looking statements included
in this communication are made as of the date of this communication
and the Company does not undertake any obligation to publicly
update such forward-looking statements to reflect new information,
subsequent events or otherwise unless required by applicable
securities laws.
Contacts:
Tilray Global:Berrin Nooratanews@tilray.com
InvestorsRaphael Gross203-682-8253Raphael.Gross@icrinc.com
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Mar 2023 to Mar 2024